Navigation Links
Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
Date:11/15/2007

for relief of osteoarthritis pain during the first quarter of 2008.

About Civamide

Civamide (cis-8-methyl-N-vanillyl-6-nonenamide) is a patented, synthetically produced agent that binds to the TRPV-1 receptor, and, in this fashion, selectively depresses the activity of the type-C pain fibers. Civamide causes an initial release of the neuropeptides, substance P (SP) and calcitonin-gene related peptide (CGRP). Pain transmission is then diminished by the subsequent depletion of SP and CGRP from the neuron, coupled with suppression of the synthesis and transport of neuropeptides along the neuron.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),regarding product development efforts and other non-historical facts about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any of our compounds under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other facto
'/>"/>

SOURCE Getting Ready Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Growing Number of U.S. Kids Not Getting Needed Vaccinations
2. U.S. Kids Not Getting Needed Health Care
3. Negative Publicity Around PFFS Sales Practices Not Getting Through to Seniors
4. Getting light to bend backwards
5. U.S. Schools Getting Better at Boosting Kids Health
6. Getting fathers involved in childrens ADHD treatment programs
7. Recognizing someones name but forgetting how you met them is all in your head
8. Consumers Open Up on RealSelf.com About Getting Work Done
9. Getting to the Root of Caring for Your Hair at Any Age
10. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
11. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Youngsters who enter puberty early are at increased risk ... was linked with a number of factors associated with ... according to the researchers. Early puberty was also linked ... peers, and having friends who were prone to getting ... found an association between early puberty and these factors, ...
(Date:11/26/2014)... Nov. 25, 2014 (HealthDay News) -- Teens prescribed ... to abuse those drugs than other teens, a ... need to conduct substance abuse assessments on teenagers ... said. "Prescribers and parents don,t realize the ... professor at the University of Michigan School of ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Exposure to peanut protein ... allergy in infants with the skin condition eczema, a ... children in the United States are allergic to peanuts. ... food allergies, particularly peanut allergy, the researchers noted. ... to 15 months. The researchers examined the amount of ...
(Date:11/26/2014)... Randy Dotinga HealthDay Reporter ... as Prilosec and Nexium may disrupt the makeup of bacteria ... and other problems, a small new study suggests. ... likely users will become ill, and study authors aren,t recommending ... However, these antacids "should be used at the lowest dose ...
(Date:11/24/2014)... Recently, Fecbek.com ( http://www.fecbek.com ), a leading ... and introduced the history of the Black Friday to its ... after Thanksgiving? It is the Black Friday! It is a ... 11th in China. However, not everyone knows the history of ... about this special day. , The fourth Friday in November ...
Breaking Medicine News(10 mins):Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
... North Carolina (UNC) at Chapel Hill have revealed that inhaling ... by cystic fibrosis (CF). Hypertonic saline// is a water-based ... ,The researchers arrived at this conclusion after testing 24 patients ... inhaling the salt solution improved the health of the lungs ...
... Pharmaceutical companies have been called upon to stop marketing ... Organization (WHO), as the parasite which causes malaria may ... Kochi, director of the WHO's malaria department, said that ... effective anti-malarials, on its own would result in the ...
... experts have warned that the new wristwatch invented by South ... can turnout to be a health hazard. They have warned ... HIV/AIDS.// There are some who have also expressed doubts if ... ,'In my mind it's a potential public health ...
... 1.107 million fowl have been killed in Turkey with the ... in the country. This has been revealed by the Turkish ... detected in as many as 13 provinces in the country, ... the bird flu has been detected are Van, Aydin, Bursa, ...
... by having their ovaries and uterus removed, if they have ... is because these women face higher chances of contracting ovarian ... as high as 40% to 60%, while it is between ... ,Women who do not have the Lynch syndrome ...
... of African Subcommittee, House Committee on International Relations has ... AIDS testing and counseling as done in Uganda. //Uganda ... effective in early diagnosis of HIV and also helps ... person due to ignorance about the disease. ...
Cached Medicine News:
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
(Date:11/26/2014)... 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... appointment of Ms. Rebecca Yingnan Zhang as ... Ms.Zhang has over 20 years of experience in ... Prior to Ms. Zhang,s appointment as the Company,s Chief ...
(Date:11/24/2014)... SEATTLE , Nov. 24, 2014 ... granted Breakthrough Therapy Designation to the company,s JCAR015 ... for the treatment of relapsed or refractory B-cell ... collaboration partner, Memorial Sloan Kettering Cancer Center, where ... "The FDA,s action is important news ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
... Cardiac Science Corporation , a global leader in automated ... monitoring devices that connect to electronic medical record ... it has completed certification with Allscripts Professional ... connectivity solution for its resting ECG, stress, and Holter ...
... and Drug Commissioner Dr. Margaret Hamburg today conducted an unusual ... a forum hosted by the National Organization for Rare Disorders ... Hamburg could share with the patient advocates her vision for ... concerns. "I come today to ask for your ...
Cached Medicine Technology:Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 2Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 4Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 5NORD Hosts Forum for FDA Commissioner and Patient Leaders 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: